Dr. Christina G Marrongelli, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 28361 Highway 35, Sardis, MS 38666 Phone: 662-703-9413 |
Brooke Lewis, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 401 E Lee St, Sardis, MS 38666 Phone: 662-487-3101 |
Kate Hall Schove Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 411 E Lee St, Sardis, MS 38666 Phone: 662-857-5173 Fax: 662-857-5163 |
Sharon Moore Massey, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 254 Walnut Rd, Sardis, MS 38666 Phone: 662-292-2447 |
News Archive
Titan Pharmaceuticals, Inc. today announced that patient enrollment is more than 60% complete in the confirmatory Phase 3 clinical study of Probuphine for the treatment of opioid addiction, and the study is expected to complete enrollment by early fourth quarter of this year, which is almost three months ahead of schedule.
Previous studies have indicated that the heparanase (HPA) is correlated with histopathological parameters and poor prognosis of gastric cancers. Although their efficiencies in inhibiting the expression of HPA, the traditional HPA inhibitors may produce nonspecific and undesirable effects. In recent years, genetic approaches targeting HPA have been regarded as a promising alternative.
Regado Biosciences, Inc., a biopharmaceutical company focused on the discovery and development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications, today announced the enrollment of the first patient in its REGULATE-PCI clinical trial.
Researchers have found, through the use of functional MRI scans that looked at the brain, that there is an abnormal activity in the some of the neurons in the brains of autistic children.
› Verified 5 days ago